Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACU301
- Development stage
- Preclinical
- Lead developer
- Acumen Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
ACU301 is a preclinical-stage bispecific antibody being developed by Acumen Pharmaceuticals for the treatment of Alzheimer's disease. It is part of Acumen's Enhanced Brain Delivery (EBD) program and is designed to target soluble amyloid-beta oligomers (AβOs) while utilizing JCR Pharmaceuticals' proprietary J-Brain Cargo blood-brain barrier (BBB)-penetrating technology. By targeting the transferrin receptor (TfR), ACU301 achieves significantly enhanced brain penetration compared to native antibodies. ACU301 is derived from sabirnetug (ACU193), Acumen's clinical-stage AβO-selective antibody. The candidate is administered subcutaneously and is undergoing IND-enabling activities, with an IND submission planned for mid-2027.
02
Targets
Aβ (Amyloid-beta peptides and aggregates)TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on ACU301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACU301.